Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Nikita C. Shah"'
Autor:
Vijay W. Dhakre, Sneha Tukaram Galande, Varsha Gunvant Patil, Nikita C Shah, Chetan Rathod, Kaiumarz S. Sethna, Anjali D Amrapurkar
Publikováno v:
Gastrointestinal Tumors.
Pancreatic adeno- Mixed neuroendocrine non-endocrine (pMINEN) are extremely rare. [1] They are known to have distal metastasis at presentation and also have a comparatively lower survival rate as compared to similar staged neuroendocrine carcinoma, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00d64c3b9e2f38d09b784ebfbfa5ac7a
https://doi.org/10.1159/000528759
https://doi.org/10.1159/000528759
Autor:
Rachel Eisenberg, Swathy Kolli, Jeff Smith, Nikita C. Shah, Eleftherios P. Mamounas, Tomas Dvorak, Michael Kahky, Terrence Gross, Marc L. Demers, Patrick J. Kelly, Cameron W. Swanick, Ana Cuesta-Fernandez, Maria Demori, Danielle A. Henry, Nirja Shah, R Rostorfer, Said Baidas
Publikováno v:
Cancer Research. 81:PS10-42
Background: Pertuzumab, a monoclonal antibody targeting subdomain II of HER2 and blocking dimerization, was approved by the FDA in 2013 as neoadjuvant therapy in combination with trastuzumab + chemotherapy for HER2+ locally advanced or early-stage br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc5aeaaea2ebacdd94dc38f7035f3a10
https://doi.org/10.1158/1538-7445.sabcs20-ps10-42
https://doi.org/10.1158/1538-7445.sabcs20-ps10-42
Publikováno v:
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH. :6-7
Benign esophageal tumors are slow growing but they rarely grow to the extent that may lead to pseudoachalasia like symptoms making complete surgical resection mandatory. We report a case of young girl presenting with dysphagia since 6 months and show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::582f6adfff584fc7a5818ad8c81615e4
https://doi.org/10.36106/ijsr/1006302
https://doi.org/10.36106/ijsr/1006302
Autor:
Aditya Bardia, Steven J. Isakoff, Sarah A. Washkowitz, Hope S. Rugo, Ingrid A. Mayer, Linda T. Vahdat, Ala M Sweidan, William A. Wegener, Alessandro D. Santin, Joyce O'Shaughnessy, Nikita C. Shah, Kevin Kalinsky, Sara M. Tolaney, Rebecca L. Moroose, Vandana G. Abramson, Jennifer R. Diamond, David M. Goldenberg, Robert Iannone, Robert M. Sharkey
Publikováno v:
New England Journal of Medicine. 380:741-751
Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac67a01c658a493abb0e34b2b312cdd
https://doi.org/10.1056/nejmoa1814213
https://doi.org/10.1056/nejmoa1814213
Autor:
Linda T. Vahdat, Aditya Bardia, Alexander Starodub, William A. Wegener, Steven J. Isakoff, Allyson J. Ocean, David M. Goldenberg, Sara M. Tolaney, Robert M. Sharkey, Nikita C. Shah, Jennifer R. Diamond, Ingrid A. Mayer, Pius Maliakal, Dejan Juric, Joyce O'Shaughnessy, Vandana Abramson, Wells A. Messersmith, Michael J. Guarino, Rebecca L. Moroose, Serengulam V. Govindan, Kevin Kalinsky, Jordan Berlin
Publikováno v:
Journal of Clinical Oncology. 2017:2141-2148
Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afb8878d0224a3477e09132be0a1092b
https://doi.org/10.1200/jco.2016.70.8297.2017.2.test
https://doi.org/10.1200/jco.2016.70.8297.2017.2.test
Publikováno v:
Cancer Research. 77:P5-16
Background: Pertuzumab, a monoclonal antibody targeting subdomain II of HER2 and blocking dimerization , was approved by the FDA in 2013 for use in combination with trastuzumab and docetaxel as neoadjuvant therapy for pts with HER2+, locally advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::187adba5f33a71b2f1150bae6397c3c7
https://doi.org/10.1158/1538-7445.sabcs16-p5-16-28
https://doi.org/10.1158/1538-7445.sabcs16-p5-16-28
Autor:
Francois Wilhelm, Vandana G. Abramson, Aditya Bardia, Kevin Kalinsky, Linda T. Vahdat, RL Moroose, Steven J. Isakoff, Ingrid A. Mayer, Jennifer R. Diamond, Dejan Juric, Jordan Berlin, Alexander Starodub, Nikita C. Shah, Wells A. Messersmith, Allyson J. Ocean, David M. Goldenberg, Joyce O'Shaughnessy, Robert M. Sharkey, Michael J. Guarino, Geoffrey I. Shapiro
Publikováno v:
Journal of Clinical Oncology. 34:LBA509-LBA509
LBA509 Notice of Retraction: “Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.” ASCO's Confidentiality Pol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76e396cfcc69034636966f03718f8ac5
https://doi.org/10.1200/jco.2016.34.18_suppl.lba509
https://doi.org/10.1200/jco.2016.34.18_suppl.lba509
Publikováno v:
Journal of Gastrointestinal & Liver Diseases. Mar2023, Vol. 32 Issue 1, p122-124. 3p.
Autor:
Dhakre, Vijay W., Galande, Sneha Tukaram, Patil, Varsha Gunvant, Shah, Nikita C., Rathod, Chetan, Sethna, Kaiumarz S., Amrapurkar, Anjali D.
Publikováno v:
Gastrointestinal Tumors; Jan-Dec2023, Vol. 10 Issue 1, p14-18, 5p